1
|
Kasatkina SO, Geyl KK, Baykov SV, Novikov MS, Boyarskiy VP. “Urea to Urea” Approach: Access to Unsymmetrical Ureas Bearing Pyridyl Substituents. Adv Synth Catal 2022. [DOI: 10.1002/adsc.202101490] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- Svetlana O. Kasatkina
- Institute of Chemistry Saint Petersburg State University Universitetskaya Nab., 7/9 Saint Petersburg 199034 Russian Federatio
| | - Kirill K. Geyl
- Institute of Chemistry Saint Petersburg State University Universitetskaya Nab., 7/9 Saint Petersburg 199034 Russian Federatio
| | - Sergey V. Baykov
- Institute of Chemistry Saint Petersburg State University Universitetskaya Nab., 7/9 Saint Petersburg 199034 Russian Federatio
| | - Mikhail S. Novikov
- Institute of Chemistry Saint Petersburg State University Universitetskaya Nab., 7/9 Saint Petersburg 199034 Russian Federatio
| | - Vadim P. Boyarskiy
- Institute of Chemistry Saint Petersburg State University Universitetskaya Nab., 7/9 Saint Petersburg 199034 Russian Federatio
| |
Collapse
|
2
|
Ji C, Jie S, Braunstein P, Li BG. Fast and controlled ring-opening polymerization of δ-valerolactone catalyzed by benzoheterocyclic urea/MTBD catalysts. Catal Sci Technol 2020. [DOI: 10.1039/d0cy01551b] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
New benzoheterocyclic urea/MTBD catalysts are highly efficient and controllable in the ring-opening polymerization of δ-valerolactone under solvent-free conditions or in solution.
Collapse
Affiliation(s)
- Chenlin Ji
- State Key Laboratory of Chemical Engineering
- College of Chemical and Biological Engineering
- Zhejiang University
- Hangzhou 310027
- China
| | - Suyun Jie
- State Key Laboratory of Chemical Engineering
- College of Chemical and Biological Engineering
- Zhejiang University
- Hangzhou 310027
- China
| | - Pierre Braunstein
- Laboratoire de Chimie de Coordination
- CNRS, CHIMIE UMR 7177
- Université de Strasbourg
- 67081 Strasbourg Cedex
- France
| | - Bo-Geng Li
- State Key Laboratory of Chemical Engineering
- College of Chemical and Biological Engineering
- Zhejiang University
- Hangzhou 310027
- China
| |
Collapse
|
3
|
Tomilov A, Allen S, Hui CK, Bettaieb A, Cortopassi G. Idebenone is a cytoprotective insulin sensitizer whose mechanism is Shc inhibition. Pharmacol Res 2018; 137:89-103. [PMID: 30290222 DOI: 10.1016/j.phrs.2018.09.024] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/07/2018] [Revised: 09/20/2018] [Accepted: 09/24/2018] [Indexed: 01/04/2023]
Abstract
When insulin binds insulin receptor, IRS1 signaling is stimulated to trigger the maximal insulin response. p52Shc protein competes directly with IRS1, thus damping and diverting maximal insulin response. Genetic reduction of p52Shc minimizes competition with IRS1, and improves insulin signaling and glucose control in mice, and improves pathophysiological consequences of hyperglycemia. Given the multiple benefits of Shc reduction in vivo, we investigated whether any of 1680 drugs used in humans may function as Shc inhibitors, and thus potentially serve as novel anti-diabetics. Of the 1680, 30 insulin sensitizers were identified by screening in vitro, and of these 30 we demonstrated that 7 bound Shc protein. Of the 7 drugs, idebenone dose-dependently bound Shc protein in the 50-100 nM range, and induced insulin sensitivity and cytoprotection in this same 100 nM range that clinically dosed idebenone reaches in human plasma. By contrast we observe mitochondrial effects of idebenone in the 5,000 nM range that are not reached in human dosing. Multiple assays of target engagement demonstrate that idebenone physically interacts with Shc protein. Idebenone sensitizes mice to insulin in two different mouse models of prediabetes. Genetic depletion of idebenone's target eliminates idebenone's ability to insulin-sensitize in vivo. Thus, idebenone is the first-in-class member of a novel category of insulin-sensitizing and cytoprotective agents, the Shc inhibitors. Idebenone is an approved drug and could be considered for other indications such as type 2 diabetes and fatty liver disease, in which insulin resistance occurs.
Collapse
Affiliation(s)
- Alexey Tomilov
- Department of Molecular Biosciences, 1089 Veterinary Medicine Dr., VM3B, UC Davis, CA, 95616, USA.
| | - Sonia Allen
- Department of Molecular Biosciences, 1089 Veterinary Medicine Dr., VM3B, UC Davis, CA, 95616, USA.
| | - Chun Kiu Hui
- Department of Molecular Biosciences, 1089 Veterinary Medicine Dr., VM3B, UC Davis, CA, 95616, USA.
| | - Ahmed Bettaieb
- Department of Nutrition, The University of Tennessee, 1215 W. Cumberland Ave, Knoxville, TN, 37996-1920, USA.
| | - Gino Cortopassi
- Department of Molecular Biosciences, 1089 Veterinary Medicine Dr., VM3B, UC Davis, CA, 95616, USA.
| |
Collapse
|
4
|
Khalid S, Hanif R, Jabeen I, Mansoor Q, Ismail M. Pharmacophore modeling for identification of anti-IGF-1R drugs and in-vitro validation of fulvestrant as a potential inhibitor. PLoS One 2018; 13:e0196312. [PMID: 29787591 PMCID: PMC5963753 DOI: 10.1371/journal.pone.0196312] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2017] [Accepted: 04/10/2018] [Indexed: 01/10/2023] Open
Abstract
Insulin-like growth factor 1 receptor (IGF-1R) is an important therapeutic target for breast cancer treatment. The alteration in the IGF-1R associated signaling network due to various genetic and environmental factors leads the system towards metastasis. The pharmacophore modeling and logical approaches have been applied to analyze the behaviour of complex regulatory network involved in breast cancer. A total of 23 inhibitors were selected to generate ligand based pharmacophore using the tool, Molecular Operating Environment (MOE). The best model consisted of three pharmacophore features: aromatic hydrophobic (HyD/Aro), hydrophobic (HyD) and hydrogen bond acceptor (HBA). This model was validated against World drug bank (WDB) database screening to identify 189 hits with the required pharmacophore features and was further screened by using Lipinski positive compounds. Finally, the most effective drug, fulvestrant, was selected. Fulvestrant is a selective estrogen receptor down regulator (SERD). This inhibitor was further studied by using both in-silico and in-vitro approaches that showed the targeted effect of fulvestrant in ER+ MCF-7 cells. Results suggested that fulvestrant has selective cytotoxic effect and a dose dependent response on IRS-1, IGF-1R, PDZK1 and ER-α in MCF-7 cells. PDZK1 can be an important inhibitory target using fulvestrant because it directly regulates IGF-1R.
Collapse
Affiliation(s)
- Samra Khalid
- Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan
- Northern Institute for Cancer Research, Newcastle upon Tyne Hospitals NHS Foundation Trust, The Medical School, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom
| | - Rumeza Hanif
- Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan
- * E-mail:
| | - Ishrat Jabeen
- Research Center for Modeling & Simulation (RCMS), National University of Sciences and Technology, Islamabad, Pakistan
| | - Qaisar Mansoor
- Institute of Biomedical and Genetic Engineering (IBGE), KRL Hospital, Islamabad, Pakistan
| | - Muhammad Ismail
- Institute of Biomedical and Genetic Engineering (IBGE), KRL Hospital, Islamabad, Pakistan
| |
Collapse
|
5
|
Benmansour F, Trist I, Coutard B, Decroly E, Querat G, Brancale A, Barral K. Discovery of novel dengue virus NS5 methyltransferase non-nucleoside inhibitors by fragment-based drug design. Eur J Med Chem 2017; 125:865-880. [DOI: 10.1016/j.ejmech.2016.10.007] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2016] [Revised: 10/03/2016] [Accepted: 10/04/2016] [Indexed: 10/20/2022]
|
6
|
Denoyelle S, Chen T, Chen L, Wang Y, Klosi E, Halperin JA, Aktas BH, Chorev M. In vitro inhibition of translation initiation by N,N'-diarylureas--potential anti-cancer agents. Bioorg Med Chem Lett 2011; 22:402-9. [PMID: 22153346 DOI: 10.1016/j.bmcl.2011.10.126] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2011] [Revised: 10/27/2011] [Accepted: 10/31/2011] [Indexed: 10/15/2022]
Abstract
Symmetrical N,N'-diarylureas: 1,3-bis(3,4-dichlorophenyl)-, 1,3-bis[4-chloro-3-(trifluoromethyl)phenyl]- and 1,3-bis[3,5-bis(trifluoromethyl)phenyl]urea, were identified as potent activators of the eIF2α kinase heme regulated inhibitor. They reduce the abundance of the eIF2·GTP·tRNA(i)(Met) ternary complex and inhibit cancer cell proliferation. An optimization process was undertaken to improve their solubility while preserving their biological activity. Non-symmetrical hybrid ureas were generated by combining one of the hydrophobic phenyl moieties present in the symmetrical ureas with the polar 3-hydroxy-tolyl moiety. O-alkylation of the later added potentially solubilizing charge bearing groups. The new non-symmetrical N,N'-diarylureas were characterized by ternary complex reporter gene and cell proliferation assays, demonstrating good bioactivities. A representative sample of these compounds potently induced phosphorylation of eIF2α and expression of CHOP at the protein and mRNA levels. These inhibitors of translation initiation may become leads for the development of potent, non-toxic, and target specific anti-cancer agents.
Collapse
Affiliation(s)
- Séverine Denoyelle
- Laboratory for Translational Research, Harvard Medical School, One Kendall Square, Building 600, 3rd Floor, Cambridge, MA 02139, USA
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Zhang L, Darko AK, Johns JI, McElwee-White L. Catalytic Oxidative Carbonylation of Arylamines to Ureas with W(CO)6/I2 as Catalyst. European J Org Chem 2011. [DOI: 10.1002/ejoc.201100657] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
8
|
Zhang Y, Anderson M, Weisman JL, Lu M, Choy CJ, Boyd VA, Price J, Sigal M, Clark J, Connelly M, Zhu F, Guiguemde WA, Jeffries C, Yang L, Lemoff A, Liou AP, Webb TR, DeRisi JL, Guy RK. Evaluation of Diarylureas for Activity Against Plasmodium falciparum. ACS Med Chem Lett 2010; 1:460-465. [PMID: 21243104 DOI: 10.1021/ml100083c] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
A library of diarylurea IGFR inhibitors was screened for activity against chloroquine-sensitive (3D7) and chloroquine-resistant (K1) strains of Plasmodium falciparum. The 4-aminoquinaldine-derived diarylureas displayed promising antimalarial potency. Further exploration of the B ring of 4-aminoquinaldinyl ureas allowed identification of several quinaldin-4-yl ureas 4{13, 39} and 4{13, 58} sufficiently potent against both 3D7 and K1 strains to qualify as bone fide leads.
Collapse
Affiliation(s)
- Yiqun Zhang
- Chemical Biology & Therapeutics Department, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38105
| | - Marc Anderson
- Department of Chemistry and Biochemistry, San Francisco State University, San Francisco, California 94132-4163
| | - Jennifer L. Weisman
- Department of Biochemistry and Biophysics
- Department of Cellular and Molecular Pharmacology
| | - Min Lu
- Chemical Biology & Therapeutics Department, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38105
| | - Cindy J. Choy
- Department of Chemistry, Washington State University, Pullman, Washington 99164-4630
| | - Vincent A. Boyd
- Chemical Biology & Therapeutics Department, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38105
| | - Jeanine Price
- Chemical Biology & Therapeutics Department, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38105
| | - Martina Sigal
- Chemical Biology & Therapeutics Department, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38105
| | - Julie Clark
- Chemical Biology & Therapeutics Department, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38105
| | - Michele Connelly
- Chemical Biology & Therapeutics Department, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38105
| | - Fangyi Zhu
- Chemical Biology & Therapeutics Department, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38105
| | - W. Armand Guiguemde
- Chemical Biology & Therapeutics Department, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38105
| | - Cynthia Jeffries
- Chemical Biology & Therapeutics Department, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38105
| | - Lei Yang
- Chemical Biology & Therapeutics Department, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38105
| | - Andrew Lemoff
- Chemical Biology & Therapeutics Department, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38105
| | | | - Thomas R. Webb
- Chemical Biology & Therapeutics Department, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38105
| | | | - R. Kiplin Guy
- Chemical Biology & Therapeutics Department, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38105
| |
Collapse
|
9
|
Engen W, O'Brien TE, Kelly B, Do J, Rillera L, Stapleton LK, Youngren JF, Anderson MO. Synthesis of aryl-heteroaryl ureas (AHUs) based on 4-aminoquinoline and their evaluation against the insulin-like growth factor receptor (IGF-1R). Bioorg Med Chem 2010; 18:5995-6005. [PMID: 20643554 DOI: 10.1016/j.bmc.2010.06.071] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2010] [Revised: 06/18/2010] [Accepted: 06/21/2010] [Indexed: 01/02/2023]
Abstract
The insulin-like growth factor receptor (IGF-1R) is a receptor tyrosine kinase (RTK) involved in all stages of the development and propagation of breast and other cancers. The inhibition of IGF-1R by small molecules remains a promising strategy to treat cancer. Herein, we explore SAR around previously characterized lead compound (1), which is an aryl-heteroaryl urea (AHU) consisting of 4-aminoquinaldine and a substituted aromatic ring system. A library of novel AHU compounds was prepared based on derivatives of the 4-aminoquinoline heterocycle (including various 2-substituted derivatives, and naphthyridines). The compounds were screened for in vitro inhibitory activity against IGF-1R, and several compounds with improved activity (3-5 microM) were identified. Furthermore, a computational docking study was performed, which identifies a fairly consistent lowest energy mode of binding for the more-active set of inhibitors in this series, while the less-active inhibitors do not adopt a consistent mode of binding.
Collapse
Affiliation(s)
- William Engen
- Department of Chemistry & Biochemistry, San Francisco State University, San Francisco, CA 94132, USA
| | | | | | | | | | | | | | | |
Collapse
|
10
|
|
11
|
Dolle RE, Le Bourdonnec B, Goodman AJ, Morales GA, Salvino JM, Zhang W. Comprehensive survey of chemical libraries for drug discovery and chemical biology: 2006. ACTA ACUST UNITED AC 2007; 9:855-902. [PMID: 17877417 DOI: 10.1021/cc700111e] [Citation(s) in RCA: 75] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Roland E Dolle
- Adolor Corporation, 700 Pennsylvania Drive, Exton, Pennsylvania 19341, USA.
| | | | | | | | | | | |
Collapse
|